Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.
A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumors, it is useful for the detection of neoplasms.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, atomic number 43, and atomic weight 98.91. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.
Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.
Pathologic deposition of calcium salts in tissues.
Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
Compression of the heart by accumulated fluid (PERICARDIAL EFFUSION) or blood (HEMOPERICARDIUM) in the PERICARDIUM surrounding the heart. The affected cardiac functions and CARDIAC OUTPUT can range from minimal to total hemodynamic collapse.
Puncture and aspiration of fluid from the PERICARDIUM.
A colorless crystalline or white powdery organic, tricarboxylic acid occurring in plants, especially citrus fruits, and used as a flavoring agent, as an antioxidant in foods, and as a sequestrating agent. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Measurement of radioactivity in the entire human body.
The measurement of radiation by photography, as in x-ray film and film badge, by Geiger-Mueller tube, and by SCINTILLATION COUNTING.
The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).
Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes.
Elements of limited time intervals, contributing to particular results or situations.
Use of a device (film badge) for measuring exposure of individuals to radiation. It is usually made of metal, plastic, or paper and loaded with one or more pieces of x-ray film.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
Four or five slender jointed digits in humans and primates, attached to each HAND.
Unstable isotopes of xenon that decay or disintegrate emitting radiation. Xe atoms with atomic weights 121-123, 125, 127, 133, 135, 137-145 are radioactive xenon isotopes.
The circulation of blood through the BLOOD VESSELS of the BRAIN.
The placing of a body or a part thereof into a liquid.
The distal part of the arm beyond the wrist in humans and primates, that includes the palm, fingers, and thumb.
A specialty field of radiology concerned with diagnostic, therapeutic, and investigative use of radioactive compounds in a pharmaceutical form.
Hospital department responsible for the administration and management of nuclear medicine services.
The application of scientific knowledge or technology to the field of radiology. The applications center mostly around x-ray or radioisotopes for diagnostic and therapeutic purposes but the technological applications of any radiation or radiologic procedure is within the scope of radiologic technology.
The exchange or transmission of ideas, attitudes, or beliefs between individuals or groups.
The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
A syndrome characterized by severe burning pain in an extremity accompanied by sudomotor, vasomotor, and trophic changes in bone without an associated specific nerve injury. This condition is most often precipitated by trauma to soft tissue or nerve complexes. The skin over the affected region is usually erythematous and demonstrates hypersensitivity to tactile stimuli and erythema. (Adams et al., Principles of Neurology, 6th ed, p1360; Pain 1995 Oct;63(1):127-33)
Conditions characterized by pain involving an extremity or other body region, HYPERESTHESIA, and localized autonomic dysfunction following injury to soft tissue or nerve. The pain is usually associated with ERYTHEMA; SKIN TEMPERATURE changes, abnormal sudomotor activity (i.e., changes in sweating due to altered sympathetic innervation) or edema. The degree of pain and other manifestations is out of proportion to that expected from the inciting event. Two subtypes of this condition have been described: type I; (REFLEX SYMPATHETIC DYSTROPHY) and type II; (CAUSALGIA). (From Pain 1995 Oct;63(1):127-33)
Interruption of sympathetic pathways, by local injection of an anesthetic agent, at any of four levels: peripheral nerve block, sympathetic ganglion block, extradural block, and subarachnoid block.
A complex regional pain syndrome characterized by burning pain and marked sensitivity to touch (HYPERESTHESIA) in the distribution of an injured peripheral nerve. Autonomic dysfunction in the form of sudomotor (i.e., sympathetic innervation to sweat glands), vasomotor, and trophic skin changes may also occur. (Adams et al., Principles of Neurology, 6th ed, p1359)
Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies.
Visible accumulations of fluid within or beneath the epidermis.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.

Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. (1/1716)

We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease. In this model, bone lesions typical of the human disease develop in mice following inoculation of myeloma cells via the tail vein. Treatment with ibandronate (4 micrograms per mouse per day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice. However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect on survival. There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels. These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth.  (+info)

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. (2/1716)

PURPOSE: To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy. PATIENTS AND METHODS: Three hundred seventy-two women with breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy were randomized to receive 90 mg of pamidronate or placebo as a 2-hour intravenous infusion given in double-blind fashion every 4 weeks for 24 cycles. Patients were evaluated for skeletal complications: pathologic fractures, spinal cord compression, irradiation of or surgery on bone, or hypercalcemia. The skeletal morbidity rate (the ratio of the number of skeletal complications to the time on trial) was the primary efficacy variable. Bone pain, use of analgesics, quality of life, performance status, bone tumor response, and biochemical parameters were also evaluated. RESULTS: One hundred eighty-two patients who received pamidronate and 189 who received placebo were assessable. The skeletal morbidity rate was significantly reduced at 12, 18, and 24 cycles in patients treated with 90 mg of pamidronate (P = .028, .023, and .008, respectively). At 24 cycles, the proportion of patients having had any skeletal complication was 56% in the pamidronate group and 67% in the placebo group (P = .027). The time to the first skeletal complication was longer for patients receiving pamidronate than for those given placebo (P = .049). There was no statistical difference in survival or in objective bone response rate. Pamidronate was well tolerated. CONCLUSION: Treatment with 90 mg of pamidronate as a 2-hour intravenous infusion every 4 weeks in addition to hormonal therapy significantly reduces skeletal morbidity from osteolytic metastases.  (+info)

Thermodynamic studies on anion binding to apotransferrin and to recombinant transferrin N-lobe half molecules. (3/1716)

Equilibrium constants for the binding of anions to apotransferrin, to the recombinant N-lobe half transferrin molecule (Tf/2N), and to a series of mutants of Tf/2N have been determined by difference UV titrations of samples in 0.1 M Hepes buffer at pH 7.4 and 25 degrees C. The anions included in this study are phosphate, sulfate, bicarbonate, pyrophosphate, methylenediphosphonic acid, and ethylenediphosphonic acid. There are no significant differences between anion binding to Tf/2N and anion binding to the N-lobe of apotransferrin. The binding of simple anions like phosphate appears to be essentially equivalent for the two apotransferrin binding sites. The binding of pyrophosphate and the diphosphonates is inequivalent, and the studies on the recombinant Tf/2N show that the stronger binding is associated with the N-terminal site. Anion binding constants for phosphate, pyrophosphate, and the diphosphonates with the N-lobe mutants K206A, K296A, and R124A have been determined. Anion binding tends to be weakest for the K296A mutant, but the variation in log K values among the three mutants is surprisingly small. It appears that the side chains of K206, K296, and R124 all make comparable contributions to anion binding. There are significant variations in the intensities of the peaks in the difference UV spectra that are generated by the titrations of the mutant apoproteins with these anions. These differences appear to be related more to variations in the molar extinction coefficients of the anion-protein complexes rather than to differences in binding constants.  (+info)

Treatment of multiple myeloma. (4/1716)

BACKGROUND AND OBJECTIVE: Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. The standard treatment with intermittent courses of melphalan and prednisone (MP) was introduced more than 30 years ago and, since then there has been little improvement in event-free and overall survival (EFS & OS). The aim of this article is to review: 1) the role of initial chemotherapy (ChT), maintenance treatment with alpha-interferon and salvage ChT, 2) the results of high-dose therapy (HDT) followed by allogeneic or autologous stem cell transplantation (allo-SCT and auto-SCT), and 3) the most important supportive measures. EVIDENCE AND INFORMATION SOURCES: The authors of this review have been actively working and contributing with original investigations on the treatment of MM during the last 15 years. In addition, the most relevant articles and recent abstracts published in journals covered by the Science Citation Index and Medline are also reviewed. STATE OF THE ART AND PERSPECTIVES: The importance of avoiding ChT in asymptomatic patients (smoldering MM) is emphasized. The criteria and patterns of response are reviewed. MP is still the standard initial ChT with a response rate of 50-60% and an OS of 2-3 years. Combination ChT usually increases the response rate but does not significantly influence survival when compared with MP. Exposure to melphalan should be avoided in patients in whom HDT followed by auto-SCT is planned, in order to not preclude the stem cell collection. The median response duration to initial ChT is 18 months. Interferon maintenance usually prolongs response duration but in most studies does not significantly influence survival (a large meta-analysis by the Myeloma Trialists' Collaborative Group in Oxford is being finished). In alkylating-resistant patients, the best rescue regimens are VBAD or VAD. In patients already resistant to VBAD or VAD and in those in whom these treatments are not feasible we recommend a conservative approach with alternate day prednisone and pulse cyclophosphamide. While HDT followed by autotransplantation is not recommended for patients with resistant relapse, patients with primary refractory disease seem to benefit from early myeloablative therapy. Although results from large randomized trials are still pending in order to establish whether early HDT intensification followed by auto-SCT is superior to continuing standard ChT in responding patients, the favorable experience with autotransplantation of the French Myeloma Intergroup supports this approach. However, although the complete response rate is higher with intensive therapy, the median duration of response is relatively short (median, 16 to 36 months), with no survival plateau. There are several ongoing trials comparing conventional ChT with HDT/autoSCT in order to identify the patients who are likely to benefit from one or another approach. With allo-SCT there is a transplant-related mortality ranging from 30 to 50% and also a high relapse rate in patients achieving CR. However, 10 to 20% of patients undergoing allo-SCT are long-term survivors (> 5 years) with no evidence of disease and, consequently, probably cured. The use of allogeneic peripheral blood stem cells (PBSC) in order to speed the engraftment and also the use of partially T-cell depleted PBSC which can decrease the incidence of graft-versus-host disease are promising approaches. In the setting of allo-SCT, donor lymphocyte infusion is an encouraging strategy in order to treat or prevent relapses. Finally, important supportive measures such as the treatment of anemia with erythropoietin, the management of renal failure and the use of bisphosphonates are reviewed.  (+info)

Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. (5/1716)

1. When injected intraperitoneally into mice in doses larger than those used clinically, all the amino derivatives of bisphosphonates (aminoBPs) tested induce a variety of inflammatory reactions such as induction of histidine decarboxylase (HDC, the histamine-forming enzyme), hypertrophy of the spleen, atrophy of the thymus, hypoglycaemia, ascites and accumulation of exudate in the thorax, and an increase in the number of macrophages and/or granulocytes in the peritoneal cavity of blood. On the other hand, dichloromethylene bisphosphonate (Cl2MBP) a typical non-aminoBP, has no such inflammatory actions. In the present study, we found that this agent can suppress the inflammatory actions of aminoBPs. 2. Cl2MBP, when injected into mice before or after injection of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP; a typical aminoBP), inhibited the induction of HDC activity by AHBuBP in a dose- and time-dependent manner. The increase in HDC activity induced by AHBuBP was largely suppressed by the injection of an equimolar dose of Cl2MBP. Cl2MBP also inhibited other AHBuBP-induced inflammatory reactions, as well as the inflammatory actions of two other aminoBPs. However, Cl2MBP did not inhibit the increase in HDC activity induced by lipopolysaccharide (LPS). 3. We have previously reported that AHBuBP augments the elevation of HDC activity and the production of interleukin-1beta (IL-1beta) that are induced by LPS. These actions of AHBuBP were also inhibited by Cl2MBP. 4. Based on these results and reported actions of bisphosphonates, the mechanisms underlying the contrasting effects of aminoBPs and Cl2MBP, a non-aminoBP are discussed. The results suggest that combined administration of Cl2MBP and an aminoBP in patients might be a useful way of suppressing the inflammatory side effects of aminoBPs.  (+info)

Host modulation as a therapeutic strategy in the treatment of periodontal disease. (6/1716)

Specific microorganisms initiate the immunoinflammatory processes that destroy tissue in periodontitis. Recent work has demonstrated, in addition to bacterial control, that modulation of the host immunoinflammatory response is also capable of controlling periodontitis. Matrix metalloproteinases (MMPs) destroy collagen and other matrix components, and the osteoclastic bone remodeling determines the periodontal bone response to a bacterial challenge. Other components of the biology, including cytokines and prostanoids, regulate MMPs and bone remodeling and are also involved in regulating the production of defensive elements, such as antibody. Agents directed at blocking MMPs or osteoclastic activity are effective in reducing periodontitis. Agents that inhibit prostaglandin E2 and selective blockage of specific cytokines have also been effective. Improved knowledge of bacterium-host interactions and of the processes leading to tissue destruction will help to identify targets for host modulation to reduce periodontitis in selected situations.  (+info)

Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH. (7/1716)

BACKGROUND: The removal of phosphate from the diet of the growing rat rapidly produces hypercalcemia, hypophosphatemia, hypercalciuria, and hypophosphaturia. Increased calcium efflux from bone has been shown to be the important cause of the hypercalcemia and hypercalciuria. It has been proposed that the increased calcium efflux from bone is osteoclast mediated. Because bisphosphonates have been shown to inhibit osteoclast-mediated bone resorption, this study was performed to determine whether bisphosphonate-induced inhibition of osteoclast function changed the biochemical and bone effects induced by phosphate depletion. METHODS: Four groups of pair-fed rats were studied: (a) low-phosphate diet (LPD; phosphate less than 0.05%), (b) LPD plus the administration of the bisphosphonate Pamidronate (APD; LPD + APD), (c) normal diet (ND, 0.6% phosphate), and (d) ND + APD. All diets contained 0.6% calcium. A high dose of APD was administered subcutaneously (0.8 mg/kg) two days before the start of the study diet and on days 2, 6, and 9 during the 11 days of the study diet. On day 10, a 24-hour urine was collected, and on day 11, rats were either sacrificed or received an additional APD dose before a 48-hour parathyroid hormone (PTH) infusion (0.066 microgram/100 g/hr) via a subcutaneously implanted miniosmotic pump. RESULTS: Serum and urinary calcium were greater in the LPD and LPD + APD groups than in the ND and ND + APD groups [serum, 11.12 +/- 0.34 and 11.57 +/- 0.45 vs. 9.49 +/- 0.17 and 9.48 +/- 0.15 mg/dl (mean +/- SE), P < 0.05; and urine, 8.78 +/- 2.74 and 16.30 +/- 4.68 vs. 0.32 +/- 0.09 and 0.67 +/- 0.28 mg/24 hr, P < 0.05]. Serum PTH and serum and urinary phosphorus were less in the LPD and LPD + APD than in the ND and ND + APD groups (P < 0.05). The calcemic response to PTH was less (P < 0.05) in the LPD and LPD + APD groups than in the ND group and was less (P = 0.05) in the LPD + APD than in the ND + APD group. Bone histology showed that phosphate depletion increased the osteoblast and osteoclast surface, and treatment with APD reduced the osteoblast surface (LPD vs. LPD + APD, 38 +/- 4 vs. 4 +/- 2%, P < 0.05, and ND vs. ND + APD, 20 +/- 2 vs. 5 +/- 2%, P < 0.05) and markedly altered osteoclast morphology by inducing cytoplasmic vacuoles. CONCLUSIONS: (a) Phosphate depletion induced hypercalcemia and hypercalciuria that were not reduced by APD administration. (b) The calcemic response to PTH was reduced in phosphate-depleted rats and was unaffected by APD administration in normal and phosphate-depleted rats, and (c) APD administration markedly changed bone histology without affecting the biochemical changes induced by phosphate depletion.  (+info)

Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. (8/1716)

BACKGROUND: Serum-based biochemical markers of bone resorption may provide better clinical information than urinary markers because direct comparison with serum markers of bone formation is possible and because the within-subject variability of serum markers may be lower. We describe a method for the measurement of free beta-1-galactosyl-O-hydroxylysine (Gal-Hyl) in serum. METHODS: The assay used preliminary ultrafiltration of serum, dansylation, and separation by reversed-phase HPLC with fluorescence detection. Healthy subjects were recruited from population-based studies of bone turnover. RESULTS: The within-run (n = 15) and between-run (n = 15) CVs were 7% and 14%, respectively, at a mean value of 48 nmol/L. In women and pubertal girls, serum free Gal-Hyl correlated with urine free Gal-Hyl (r = 0.84; P <0.001). Serum Gal-Hyl was higher during puberty and increased after menopause. The fractional renal clearance of free Gal-Hyl relative to that of creatinine was 0.90 (95% confidence interval, 0.82-0.98). Serum free Gal-Hyl decreased by 36% (SE = 4%) in 14 patients with mild Paget disease treated with an oral bisphosphonate, and this decrease was significantly (P <0. 001) greater than that seen for either serum tartrate-resistant acid phosphatase (9%; SE = 4%) or serum C-terminal telopeptide of collagen I (19%; SE = 8%). CONCLUSION: Serum free Gal-Hyl may be useful as a serum marker of bone resorption.  (+info)

TY - JOUR. T1 - Cancer treatment-induced bone loss in premenopausal women. T2 - A need for therapeutic intervention?. AU - Hadji, P.. AU - Gnant, M.. AU - Body, J. J.. AU - Bundred, N. J.. AU - Brufsky, A.. AU - Coleman, R. E.. AU - Guise, T. A.. AU - Lipton, A.. AU - Aapro, M. S.. PY - 2012/10/1. Y1 - 2012/10/1. N2 - Current clinical treatment guidelines recommend cytotoxic chemotherapy, endocrine therapy, or both (with targeted therapy if indicated) for premenopausal women with early-stage breast cancer, depending on the biologic characteristics of the primary tumor. Some of these therapies can induce premature menopause or are specifically designed to suppress ovarian function and reduce circulating estrogen levels. In addition to bone loss associated with low estrogen levels, cytotoxic chemotherapy may have a direct negative effect on bone metabolism. As a result, cancer treatment-induced bone loss poses a significant threat to bone health in premenopausal women with breast cancer. Clinical ...
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year. INTRODUCTION: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in osteoporosis, evidence from randomized clinical trials in several other chronic conditions shows that reducing dosing frequency enhances therapeutic adherence. Ibandronate is a new and potent bisphosphonate with antifracture efficacy proven for daily administration and also intermittent administration with a dose-free interval of |2 months. This report presents comparative data on the efficacy and safety of monthly and daily oral ibandronate regimens. MATERIALS AND METHODS: MOBILE is a 2-year, randomized, double-blind,
A single dose of zoledronic acid should not exceed 5 mg and the duration of infusion should be no less than 15 minutes [see Dosage and Administration (2)].. Zoledronic Acid Injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment [see Contraindications (4)]. If history or physical signs suggest dehydration, Zoledronic Acid Injection therapy should be withheld until normovolemic status has been achieved [see Adverse Reactions (6.2)].. Zoledronic acid should be used with caution in patients with chronic renal impairment. Acute renal impairment, including renal failure, has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal compromise, advanced age, concomitant nephrotoxic medications, concomitant diuretic therapy, or severe dehydration occurring before or after zoledronic acid administration. Acute renal failure (ARF) has been observed in patients after a ...
A single dose of zoledronic acid should not exceed 5 mg and the duration of infusion should be no less than 15 minutes [see Dosage and Administration (2)].. Zoledronic Acid Injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment [see Contraindications (4)]. If history or physical signs suggest dehydration, Zoledronic Acid Injection therapy should be withheld until normovolemic status has been achieved [see Adverse Reactions (6.2)].. Zoledronic acid should be used with caution in patients with chronic renal impairment. Acute renal impairment, including renal failure, has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal compromise, advanced age, concomitant nephrotoxic medications, concomitant diuretic therapy, or severe dehydration occurring before or after zoledronic acid administration. Acute renal failure (ARF) has been observed in patients after a ...
A small series of aminobisphosphonates (N-BPs) structurally related to zoledronic acid was synthesized with the aim of improving activity toward activation of human gammadelta T cells and in turn their in vivo antitumor activity. The absence of the 1-OH moiety, together with the position and the different basicity of the nitrogen, appears crucial for antitumor activity. In comparison to zoledronic acid, compound 6a shows a greater ability to activate gammadelta T cells expression (100 times more) and a proapoptotic effect that is better than zoledronic acid. The potent activation of gammadelta T cells, in addition to evidence of the in vivo antitumor activity of 6a, suggests it may be a new potential drug candidate for cancer treatment.
The maximum recommended dose of zoledronic acid in hypercalcemia of malignancy (albumin-corrected serum calcium greater than or equal to 12 mg/dL [3.0 mmol/L]) is 4 mg. The 4 mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes. Patients who receive zoledronic acid should have serum creatinine assessed prior to each treatment.. Dose adjustments of zoledronic acid are not necessary in treating patients for hypercalcemia of malignancy presenting with mild-to-moderate renal impairment prior to initiation of therapy (serum creatinine less than 400 µmol/L or less than 4.5 mg/dL).. Patients should be adequately rehydrated prior to administration of zoledronic acid [see Warnings and Precautions (5.2)].. Consideration should be given to the severity of, as well as the symptoms of, tumor-induced hypercalcemia when considering use of zoledronic acid. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should ...
Prior to administration of each dose of zoledronic acid, obtain a serum creatinine and creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid dose. Zoledronic acid is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment. A 5 mg dose of zoledronic acid administered intravenously is recommended for patients with creatinine clearance greater than or equal to 35 mL/min. There are no safety or efficacy data to support the adjustment of the zoledronic acid dose based on baseline renal function. Therefore, no dose adjustment is required in patients with CrCl greater than or equal to 35 mL/min [see Contraindications (4), Warnings and Precautions (5.3)] ...
Background: Intravenous bisphosphonates are the current standard of care for the treatment of hypercalcemia of malignancy and for the prevention of skeletal complications associated with bone metastases. Recently, retrospective case studies have reported an association between long-term bisphosphonate therapy and osteonecrosis of the jaws. Patients and Methods: The data for twelve patients, referred to either an oral and maxillofacial surgeon or to an oral medicine specialist for the management of clinically apparent chronic oral osteonecrosis of unknown etiology. were reviewed. All had received cancer-related therapy simultaneously with bisphosphonate management. Results: The typical presenting symptoms were pain and exposed bone at the site of a previous tooth extraction. In most patients, the lesions initially occurred after dental extraction or other odonto-stomatological procedures, while five had a spontaneous event. Biopsy of the involved area showed the presence of necrotic lacunae, with ...
TY - JOUR. T1 - The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. AU - Casuccio, Alessandra. AU - Badalamenti, Giuseppe. AU - Fulfaro, Fabio. AU - Leto, Gaetano. AU - Cicero, Giuseppe. AU - Russo, Antonio. AU - Di Fede, Gaetana. AU - Rini, Giovam Battista. AU - Gebbia, Nicolo. AU - Gebbia, Nicola. AU - Arcara, Carmelo Carlo. AU - Intrivici, Chiara. PY - 2005. Y1 - 2005. N2 - Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. We have carried out a perspective study on 24 consecutive patients with prostate cancer metastatic to bone to verify the effect of zoledronic acid on analgesic response and a possible relationship with the levels of bone metabolism biomarkers. Eligibility for this study required prostate cancer patients with metastatic bone disease and pain not controlled by analgesics. Patients were excluded from the study if they ...
[117 Pages Report] Check for Discount on Global Bisphosphonate Drugs Sales Market Report 2016 report by QYResearch Group. Notes: Sales, means the sales volume of Bisphosphonate Drugs Revenue,...
In QResearch 4.6% of cases and 4.5% of controls had one or more prescriptions for bisphosphonates, as did 4.8% and 4.6%, respectively, in CPRD. About two thirds of patients with a diagnosis of osteoporosis had been prescribed bisphosphonates (64% of cases and 65% of controls in QResearch and 61% and 60%, respectively, in CPRD) and 2% of cases and controls in both databases had prescriptions for bisphosphonates without records of osteoporosis. Bisphosphonate users were more likely to be women and to have a lower BMI. Upper gastrointestinal problems were slightly more common (QResearch: cases 25% in users v 22% in non-users, controls 25% v 20%; CPRD: cases 35% v 29%, controls 33% v 27%) and use of acid lowering drugs was much more common in bisphosphonate users (QResearch: cases 62% in users v 37% in non-users, controls 61% v 32; CPRD: cases 65% v 39%, controls 63% v35%). Among bisphosphonate users, the proportion of patients with rheumatoid arthritis was more than five times higher than in ...
Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than 1 years duration) bisphosphonate use for the treatment of post-menopausal osteoporosis or other benign bone disease is associated with impaired dental healing. A case-control study has been chosen to test the hypothesis as the outcome event rate is likely to be very low. A total of 54 cases will be recruited into the study
TY - JOUR. T1 - Statins prevent bisphosphonate-induced ¿d-T-cell proliferation and activation in vitro. AU - Thompson, Keith. AU - Rogers, Michael John. PY - 2004/2. Y1 - 2004/2. N2 - Introduction: The acute phase response is the major adverse effect of intravenously administered nitrogen-containing bisphosphonate drugs (N-BPs), used in the treatment of metabolic bone diseases. This effect has recently been attributed to their action as non-peptide antigens and direct stimulation of gamma,delta-T-cells. However, because N-BPs are potent inhibitors of farnesyl diphosphate (FPP) synthase, they could cause indirect activation of gamma,delta-T-cells owing to the accumulation of intermediates upstream of FPP synthase in the mevalonate pathway, such as isopentenyl diphosphate/dimethylallyl diphosphate, which are known gamma,delta-T-cell agonists.Materials and Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and treated with N-BP, statin, or ...
Reclast zoledronic acid - How long is fasting required before reclast (zoledronic acid) is taken? Good news for you! Hi. You DO NOT HAVE TO FAST before, during, or after Reclast (zoledronic acid) being given! Reclast (zoledronic acid) is given intravenously, bypassing the GI tract entirely (unlike the oral bisphosphonates, which require fasting). Bon appetite!
The geminal bisphosphonates are a new class of drugs characterised by a P-C-P bond. Consequently, they are analogues of pyrophosphate, but are resistant to chemical and enzymatic hydrolysis. The bisphosphonates bind strongly to hydroxyapatite crystals and inhibit their formation and dissolution. This physicochemical effect leads in vivo to the prevention of soft tissue calcification and, in some instances, inhibition of normal calcification. The main effect is to inhibit bone resorption, but in contrast to the effect on mineralisation, the mechanism involved is cellular. These various effects vary greatly according to the structure of the individual bisphosphonate. The half-life of circulating bisphosphonates is very brief, in the order of minutes to hours. 20% to 50% of a given dose is taken up by the skeleton, the rest being excreted in the urine. The half-life in bone is far longer and depends upon the turnover rate of the skeleton itself. Bisphosphonates are very well tolerated; the ...
THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ --. Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published in The Lancet, met its primary and secondary endpoints and demonstrated XGEVAs superiority compared to Zometa in preventing SREs. XGEVA was approved by the U.S. Food and Drug Administration (FDA) on Nov. 18, 2010 for the prevention of SREs in patients with bone metastases from solid tumors, including prostate cancer. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. XGEVA, the first and only FDA-approved RANK Ligand inhibitor, is the first new treatment for advanced cancer patients with bone metastases in nearly a decade. Bone metastases represent a significant risk for advanced prostate ...
Zometa (chemical name: zoledronic acid) is used to strengthen bones in women diagnosed with metastatic breast cancer that has spread to the bones. Zometa also is used to lower the risk of a skeletal-related event. Zometa is given intravenously, usually every 4 weeks. A study suggests that after a year, women with bone metastases can get Zometa every 12 weeks and still get the same benefits from the medicine, while reducing their risk of side effects. The research was presented at the 2014 American Society of Clinical Oncology Annual Meeting on May 31, 2014. Read the abstract of Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. Dr. Gabriel Hortobagyi, professor of medical oncology at the University of Texas MD Anderson Cancer Center, presented the study. Dr. Hortobagyi also is a member of the Breastcancer.org Professional Advisory Board. Zometa is a bisphosphonate. ...
Injectable formulation of bisphosphonate (pamidronate, alendronate, incadronate, and zoledronate) is available only for therapy of malignancy in Japan. Ibandronate and zoledronate are permitted to use by injection in the treatment of osteoporosis in US and Europe and have shown a significant effect in fracture prevention. Recently, it was reported that an annual infusion of zoledronate was associated with improved survival in addition to a reduction in the rate of new fractures. Injectable formulation of ibandronate is now in the 3rd phase of clinical trial for fracture prevention in Japan. It is expected that patients with a high fracture risk who could not take bisphosphonate orally receive the benefit of bisphosphonate through injection.
This phase II study will evaluate the efficacy of radiotherapy in combination with zoledronic acid on pain relief and the safety of radiotherapy in bone
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis Ege Can Serefoglu1, Zafer Tandogdu21Kiziltepe Hospital, Department of Urology, Mardin, Turkey; 2Taksim Teaching Hospital, Department of Urology, Istanbul, TurkeyAbstract: Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment
Longer intervals between zoledronic acid doses for patients with bone metastases did not result in an increased risk of skeletal-related events (SREs).
In this study, we developed a cost-effectiveness simulation using a Markov model to evaluate the cost-effectiveness of 4 treatment strategies for men with advanced hormone-naive prostate cancer based on the STAMPEDE trial. The ICER of SOC plus zoledronic acid, SOC plus docetaxel, and SOC plus zoledronic acid/docetaxel were $100,802.75/QALY, $38,977.15/QALY, and $89,782.46/QALY, respectively, compared with SOC alone, indicating that SOC plus zoledronic acid, SOC plus docetaxel, and SOC plus zoledronic acid/docetaxel are unlikely to be cost-effective compared with SOC alone based on a WTP threshold of $20,301.00/QALY.. Although a significant OS improvement for ADT plus docetaxel versus ADT alone was seen in the STAMPEDE trial, which was consistent with the result of the CHAARTED-E3805 trial (24), the addition of docetaxel to ADT did not show a significant OS benefit versus ADT alone in the GETUG-AFU 15 trial (25). Discrepancies between the GETUG-AFU15 trial and the CHAARTED-E3805 or STAMPEDE ...
TY - JOUR. T1 - Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. AU - Keizman, Daniel. AU - Ish-Shalom, Maya. AU - Pili, Roberto. AU - Hammers, Hans. AU - Eisenberger, Mario A.. AU - Sinibaldi, Victoria. AU - Boursi, Ben. AU - Maimon, Natalie. AU - Gottfried, Maya. AU - Hayat, Henry. AU - Peer, Avivit. AU - Kovel, Svetlana. AU - Sella, Avishay. AU - Berger, Raanan. AU - Carducci, Michael A.. PY - 2012/5/1. Y1 - 2012/5/1. N2 - Background: Bisphosphonates are used to prevent skeletal events of bone metastases, and may exhibit antitumour effects. We aimed to evaluate whether bisphosphonates can bring a response rate (RR), progression free survival (PFS) and overall survival (OS) benefit to patients with bone metastasis from renal cell carcinoma (RCC) that is treated with sunitinib. Methods: We performed a multicentre retrospective study of patients with bone metastases ...
Chronic diffuse sclerosing osteomyelitis (CDSO) is a condition of unknown aetiology which causes sclerosis, predominantly in the long bones and mandible of young women. We report the cases of three women treated with the intravenous bisphosphonate ibandronate, a new treatment for the disease, and discuss the relevance of the bone marker changes seen in these patients.. Case one is a 27 year old woman diagnosed with CDSO at age 21, when she presented with severe and intractable pain in the left thigh. An x ray examination and magnetic resonance imaging confirmed diffuse cortical thickening with reduced medullary cavity, and bone biopsy confirmed the diagnosis ...
Our study demonstrates a dose-dependent and time-dependent cytotoxic effect of zoledronic acid on breast cancer cells in vitro. These results are consistent with earlier reports that zoledronic acid can inhibit breast cancer cell proliferation and invasion, and can induce apoptosis [14-16]. These studies reported cell growth inhibition levels closer to our results, between 50 and 100 μM.. Current trends in the treatment of human tumors are with drug combination. This approach results in improved responses as well as the ability to use lower, less toxic concentrations of the drugs. In clinical practice, metastatic breast cancer patients would rarely be treated with BPs alone, and may instead be given drug combinations such as anthracyclines and taxoids. The antitumor effect of BPs can therefore also be enhanced by coadministration of chemotherapeutic agents. We recently showed that zoledronic acid inhibits cell growth and synergistically induces apoptosis with dexamethasone and thalidomide on ...
Breast cancer very commonly metastasizes to bone, often with devastating consequences, including pain, pathological fractures, hypercalcaemia and nerve compression syndromes. Bisphosphonates are very effective in the management of bone secondaries from breast cancer. Recent clinical studies have also suggested that adjuvant oral clodronate in patients with primary breast cancer may confer a survival benefit thereby raising the possibility that bisphosphonates have an anti-tumour effect. The aim of this PhD was to determine whether bisphosphonates have an anti-tumour effect on human breast cancer cells. The potent third generation bisphosphonate, zoledronic acid, was found to reduce cell number and increase apoptosis, mediated by inhibition of the mevalonate pathway, in human breast cancer cells in vitro. The effects on cell apoptosis were shown to be synergistic when zoledronic acid was combined with a chemotherapeutic agent, paclitaxel. To extend the investigation to the in vivo setting, we ...
The Bisphosphonates market is mainly driven by the incidence and prevalence rate of bone diseases. The expansion in geriatric population is the major driver for the bisphosphonates market. Ageing people start losing bone density and may suffer from fractures therefore bisphosphonate treatment becomes necessary for such patients. According to the U.S. Department of Health and Human Services, 2013 survey, nearly 14.1% of the U.S. population was aged above 65 years and is increasing rapidly. Another significant factor favorable for the growth of bisphosphonates market is the escalation in the number of women in the post-menopausal stage, who suffer from the weakening bones. The total number of women attaining menopause is estimated to cross 1 bn. by 2025, according to the International Menopause Society the number of menopausal women is higher in the developing. Incidence rate of cancers like myeloma which cause loss of bone density. Bisphosphonates are also used for therapy in the patients ...
Painful large and unresectable bone cysts responded rapidly to IV biphosphonate therapy within first cycle in 88% of cases. Adults received 4 mg of Zoledronic acid (Zometa®, Novartis), and children got IV pamidronate 1mg/kg. Zoledronic acid, if more than one was needed, was cycled every 1-2.7 months; pamidronate was cycled every 2.7 - 6 months.. ...
PRIMARY OBJECTIVES:. I. To determine whether every-12-week therapy with zoledronic acid is not inferior to every-4-week therapy for patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma involving bone, as measured by the proportion who experience at least one skeletal related event within 24 months after randomization.. SECONDARY OBJECTIVES:. I. To compare pain scores (Brief Pain Inventory) of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing.. II. To compare the functional status (Eastern Cooperative Oncology Group [ECOG] performance status) of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing.. III. To compare the incidence of osteonecrosis of the jaw in patients with metastatic breast cancer, ...
Multiple Myeloma and Bone Metastases of Solid Tumors. The safety analysis includes patients treated in the core and extension phases of the trials. The analysis includes the 2042 patients treated with zoledronic acid 4 mg, pamidronate 90 mg, or placebo in the three controlled multicenter bone metastases trials, including 969 patients completing the efficacy phase of the trial, and 619 patients that continued in the safety extension phase. Only 347 patients completed the extension phases and were followed for 2 years (or 21 months for the other solid tumor patients). The median duration of exposure for safety analysis for zoledronic acid 4 mg (core plus extension phases) was 12.8 months for breast cancer and multiple myeloma, 10.8 months for prostate cancer, and 4.0 months for other solid tumors.. Table 6 describes adverse events that were reported by 10% or more of patients. Adverse events are listed regardless of presumed causality to study drug.. ...
Objective Osteonecrosis of the jaws (ONJ) is a well known side effect of bisphosphonate therapies in patients with multiple myeloma or other malignancies. Its real incidence is still undetermined, and only few cases of ONJ in patients taking bisphosphonates for non-oncologic diseases have been reported. It was postulated that the clinical features, predisposing factors, and treatment outcome of this subset of patients might be different from those of oncologic patients. Methods Over a 4 year period, a total of 102 bisphosphonate-treated patients affected by ONJ were identified. Among these, 24 patients underwent bisphosphonate therapy for non-neoplastic disease and their profile was analyzed. Results In this study cohort, bisphosphonates had been administered mainly for postmenopausal osteoporosis (20/24 patients, 83.3%), the duration of therapy until presentation of ONJ ranging from 11 to 40 months and the most common triggering event being dentoalveolar surgery. All patients were nonsmokers; 6 ...
Zoledronic Acid (ZA) is a potent nitrogen-containing bisphosphonates (NBP) has been extensively used to limit bone turnover in a various diseases including tumors. Recently, clinical trails of Zoledronic Acid demonstrated direct anti-cancer effects as well as the known skeletal-related events. We investigated the effect of 4 NBPs on human tumor cells proliferation and found ZA is most potent for GBM cell, breast cell and GBM patients stem-cell-like cells. ZA also effectively inhibited GBM tumor growth in mouse model. ZA stimulated strong autophagy but not apoptotic signals in all tested cells. One intermediate product of cholesterols synthesis pathway--geranylgeranyl diphosphate (GGPP) rescued cell from the cytotoxicity of ZA. Knock-down RABGGTA, which encoded a subunit of the Rab geranylgeranyltransferase proteins, induced a similar effect as Zoledronic Acid in cancer cell lines. These data suggested great potential for Zoledronic Acid against human cancer.. Note: This abstract was not ...
Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use this medication.. Deterioration of the jaw bone: People with cancer treated with pamidronate (or other bisphosphonates) may rarely develop osteonecrosis of the jaw (deterioration of the jaw bone). If you experience any pain, swelling, or infection of the jaw, report this to your doctor. Before starting treatment with pamidronate, your doctor may recommend that you see a dentist for an examination and any necessary dental treatment. While receiving pamidronate, people should avoid invasive dental procedures such as tooth extractions.. Drowsiness/reduced alertness: Pamidronate may cause drowsiness and dizziness. Avoid driving, operating potentially dangerous machinery, or participating in other activities that ...
Oral regimens for the treatment of osteoporosis, mostly oral bisphosphonates, expose only low efficacy due to their relatively high rate of side-effects and adverse events, with very low persistence rates [2] of about 30% and 9% after 1 and 5 years, respectively [3]. The introduction of intravenous bisphosphonates improved persistence and rendered possible for the first time reliable study outcomes on the efficacy and safety of these drugs, particularly of zoledronic acid, as described in the paper by Black and colleagues [1]. Nevertheless, according to a former study, approximately one-third of patients treated with zoledronic acid suffer from post-infusion symptoms such as pyrexia, influenza-like symptoms, myalgia, headache and arthralgia after the first infusion, and the number of patients with arrhythmia or serious atrial fibrillation is significantly higher in the zoledronic acid group than in the placebo group [4]. Such side-effects and adverse events might be one reason for the small ...
Progerias are rare premature aging diseases in which children die of severe atherosclerosis leading to strokes and heart attacks. It is a multisystem disease with objective clinical markers for disease progression. These include abnormalities in growth and body composition, bone mineral density, join function, endocrine function, alopecia, and vascular disease. There is currently no therapy proven effective for any of the progressive and deleterious aspects of this disorder.. Progeria is caused by a gene defect in the gene LMNA, coding for the nuclear protein lamin A. Lamin A is normally expressed by most differentiated cells, and requires posttranslational farnesylation to incorporate into the nuclear membrane. This trial proposes to use three agents (zoledronic acid, pravastatin, and lonafarnib) to inhibit farnesylation of abnormal lamin, the disease causing protein in Progeria. The primary objective of this study is to evaluate the feasibility of administering intravenous zoledronic acid, ...
What were presenting here is the first presentation of a very large double-blind randomised trial comparing the use of zoledronic acid, which is kind of the standard of care for the treatment of myeloma related bone disease, to denosumab which is a monoclonal antibody directed against RANK ligand. It is the first time we are presenting this dataset; it is one of the largest multi-centre international trials of close to a little over 1,700 patients actually, so one of the largest international trials that we are presenting in myeloma. The other nice thing about this trial is all of these patients, in fact, the eligibility was that these are newly diagnosed patients comparing standard of care of zoledronic acid with denosumab as bone targeted treatment for myeloma.. What methods did you use?. Like I said, this was a double blind randomised trial; we have over 1,700 patients in this trial. It was a one to one randomisation with half the patients getting zoledronic acid plus placebo versus the ...
In QResearch 4.6% of cases and 4.5% of controls had one or more prescriptions for bisphosphonates, as did 4.8% and 4.6%, respectively, in CPRD. About two thirds of patients with a diagnosis of osteoporosis had been prescribed bisphosphonates (64% of cases and 65% of controls in QResearch and 61% and 60%, respectively, in CPRD) and 2% of cases and controls in both databases had prescriptions for bisphosphonates without records of osteoporosis. Bisphosphonate users were more likely to be women and to have a lower BMI. Upper gastrointestinal problems were slightly more common (QResearch: cases 25% in users v 22% in non-users, controls 25% v 20%; CPRD: cases 35% v 29%, controls 33% v 27%) and use of acid lowering drugs was much more common in bisphosphonate users (QResearch: cases 62% in users v 37% in non-users, controls 61% v 32; CPRD: cases 65% v 39%, controls 63% v35%). Among bisphosphonate users, the proportion of patients with rheumatoid arthritis was more than five times higher than in ...
Background: Osteogenesis imperfecta (OI) is a heritable disease marked by a varying degree of low bone mass and increased incidence of fractures. Approximately 1 in 15 000 and 1 in 20 000 children are affected by this connective tissue disorder. Although, the mainstay of treatment for children and adolescents with OI is multidisciplinary, the role of bisphosphonates is rapidly becoming the standard of care. Bisphosphonates work by inhibiting osteoclast mediated bone resorption, therefore, allowing osteoblast more time for bone formation. Currently, very little is known about the effect of oral bisphosphonate treatment; despite it being under investigation in controlled trials. This can be attributed to the lack of blinding and relatively small study populations in previous reviewed studies. Therefore, the purpose of this systematic review is to determine the efficacy of bisphosphonates in increasing bone mineral density and decreasing the incidence of fractures in a larger study population with adequate
Throughout the courses, the view Bisphosphonates in Clinical Oncology: The Development to Finite part tank and property teaching comes laid, Taking an creation in residual items. materials have fueled for supposed phones of settings and around commercially-funded environments like methods, view Bisphosphonates in Clinical, and learning which is suitable aspects to create less and are more in the flat network. easy things in view Bisphosphonates in Clinical Oncology: competition, little as the school of stress modes, the student of e-mail and the promotion of Indigenous time representativeness using, are been more hours to have from rate as than changing. Although this can be well in the view Bisphosphonates in Clinical Oncology: The Development of Pamidronate 1999 or in the stereotypes, the boy begins possibly putting, which is against the largest Program of the world energy, which enables easier drilling to power and teachers racial to student. off, the view of fluid physics is time basics, ...
Please see the individual PI for full indication and prescribing information.. Zoledronic Acid Injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) , 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL=Ca in mg/dL + 0.8 (4.0 g/dL _ patient albumin (g/dL)).. Zoledronic Acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.. Zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.. ...
Breast cancer: Bisphosphonate therapy has been shown to prevent or delay bone destruction and related pain in women with breast cancer that has spread to the bone. In a large clinical trial, a total of 751 women with metastatic breast cancer were randomly assigned to receive the bisphosphonate drug, Aredia®, or placebo (inactive substitute). The results showed that 64% of women who received the placebo had significant bone damage, compared with only 51% of those who received the bisphosphonate. The average time to the occurrence of the first bone complication was 13 months in the bisphosphonate group, compared to only 7 months in the placebo group. Furthermore, women who did not receive the bisphosphonate experienced significantly more pain and received more pain medications.2. Learn more at the Breast Cancer Information Center. Prostate cancer: Zometa® has been shown to be a safe and effective treatment in prostate cancer patients with bone metastases. Zometa® significantly reduces the ...
Zoledronic acid (sometimes called zoledronate) is a bisphosphonate (bis FOS fo nayt) medicine that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. Reclast and Zometa are two different brands of zoledronic acid. Reclast is used to treat osteoporosis...
In this study, we aimed to evaluate the cytotoxic and apoptotic effects of zoledronic acid on K562 chronic myeloid leukemia (CML) cells and to examine the roles of STAT genes on zoledronic acid-induced apoptosis. The results showed that zoledronic acid decreased proliferation, and induced apoptosis in K562 cells in a dose- and time-dependent manner. mRNA and protein levels of STAT3, -5A and -5B genes were significantly reduced in zoledronic acid-treated K562 cells. These data indicated that STAT inhibition by zoledronic acid may be therapeutic in CML patients following the confirmation with clinical studies. (C) 2013 Elsevier Masson SAS. All rights reserved. ...
In breast cancer patients, bone is the most common site of metastases. Medical therapies are the basic therapy to prevent distant metastases and recurrence and to cure them. Radiotherapy has a primary role in pain relief, recalcification and stabilization of the bone, as well as the reduction of the risk of complications (e.g., bone fractures, spinal cord compression). Bisphosphonates, as potent inhibitors of osteoclastic-mediated bone resorption are a well-established, standard-of-care treatment option to reduce the frequency, severity and time of onset of the skeletal related events in breast cancer patients with bone metastases. Moreover bisphosphonates prevent cancer treatment-induced bone loss. Recent data shows the anti-tumor activity of bisphosphonates, in particular, in postmenopausal women and in older premenopausal women with hormone-sensitive disease treated with ovarian suppression. Pain is the most frequent symptom reported in patients with bone metastases, and its prevention and treatment
TY - JOUR. T1 - Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. AU - Kok, Dieke H. J.. AU - Sakkers, Ralph J. B. AU - Janse, Arieke J. AU - Pruijs, Hans E. H. AU - Verbout, Ab J. AU - Castelein, Rene M.. AU - Engelbert, Raoul H H. N1 - Open access article-license unspecified. PY - 2007/11. Y1 - 2007/11. N2 - In this double-blind randomised placebo-controlled trial it was investigated during a two-year follow-up whether oral bisphosphonates (Olpadronate 10 mg/m2/day) influence quality of life in children with osteogenesis imperfecta (OI). Thirty-four children with OI (classified according to Sillence criteria), aged 3 to 18 years of age, with a restricted level of ambulation were included. Randomisation was performed using a list of computer generated random numbers to allocate patients to receive Olpadronate or placebo. Quality of life was measured using self-perception profile for children ...
Osteoporosis and low bone mass are currently estimated to be a major public health risk affecting |50% of the female population over the age of 50. Because of their bone-selective pharmacokinetics, nitrogen-containing bisphosphonates (N-BPs), currently used as clinical inhibitors of bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit protein prenylation. FPPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate. To understand the molecular events involved in inhibition of FPPS by N-BPs, we used protein crystallography, enzyme kinetics, and isothermal titration calorimetry. We report here high-resolution x-ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clinical use. These agents bind to the dimethylallyl/geranyl pyrophosphate ligand pocket and induce a conformational change. The
Bisphosphonates are therapeutically applied to treat metabolic bone diseases, such as osteoporosis or metastasis to the bone. Clinical studies have shown their potency to increase bone density over an extended period of time [25-28]. This effect is not only caused by a positive bone turnover, but also by a direct stimulation of osteoblast and osteoblast precursor cells by applying nitrogen-containing bisphosphonates [15, 29]. An anabolic effect to the bone could be caused by proliferation and by extracellular matrix production, mainly of collagen type I. With respect to osteoblast proliferation, we examined cyclin D1, an important regulator of the cell cycle and a surrogate of cell proliferation. Our results did not show a significant impact on osteoblast proliferation during the first 6 days. However, after day 6 zoledronate led to a reduced Cyclin D1 gene expression. As shown in other in vitro studies, pamidronate, a nitrogen-containing bisphosphonate, decreased osteoblast proliferation in a ...
The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Bisphosphonates are generally considered as safe drugs but, can be associated with laboratory abnormalities, particularly, elevated serum creatinine levels and hypocalcemia.[1] Sporadic episodes of acute and subacute renal failure have been reported, whereas hypocalcemia has not yet been the subject of detailed research.. Theoretically, intravenous bisphosphonate guarantees 100% absorption without gastrointestinal adverse effects thereby advantageous over oral bisphosphonate. Particularly, zoledronate has gained popularity as an osteoporosis treatment since its injection time (15 minutes) is shorter than that of other intravenous bisphosphonates and the injection is performed only once a year.. Maximum plasma concentrations of zoledronic acid are reached, as expected, at the end of the IV infusion. Blood levels then rapidly decline to less than 10% at four hours and to less than 1% at 24 hours after infusion. Half-life is known to be as long as 146 hours.[2] About 61% of the administered dose is ...
This study evaluated the effect of anti-osteoporosis treatment with intravenous zoledronic acid during the perioperative period, on the adjacent vertebral body bone mineral density (BMD) after spinal fusion surgery in postmenopausal women with osteoporosis. All data were collected retrospectively from patients medical records using standardized forms, including: demographics (age, BMI, years since menopause); surgical details of levels included (fusion level and cephalad levels); and BMD values. BMD values (g/cm2) were recorded for the overall lumbar spine, for the levels cephalad to the fused segments, and the femoral neck. The group 0 represents the treated group and group 1 represents the untreated group. The table 1 shows the data about the description of demographic and surgery information of treated group and untreated group. Additionally, the table 2 shows the information about cephalad adjacent vertebral and femoral neck BMD value change. The conclusion shows that perioperative zoledronic acid
TY - JOUR. T1 - Clinical usefulness of bisphosphonates in oncology. T2 - Treatment of bone metastases, antitumoral activity and effect on bone resorption markers. AU - Verì, A.. AU - DAndrea, M. R.. AU - Bonginelli, P.. AU - Gasparini, Giampietro. PY - 2007/1. Y1 - 2007/1. N2 - The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal-related events, and pain control. Bisphosphonates are used to prevent pathological fractures by ...
In this study, we analyzed the influence of mesenchymal stromal cells derived from lymph nodes of non-Hodgkin lymphomas, on effector functions and differentiation of Vδ2 T lymphocytes. We show that: i) lymph-node mesenchymal stromal cells of non-Hodgkin lymphoma inhibit NKG2D-mediated lymphoid cell killing, but not rituximab-induced antibody-dependent cell-mediated cytotoxicity, exerted by Vδ2 T lymphocytes; ii) pre-treatment of mesenchymal stromal cells with the aminobisphosphonates pamidronate or zoledronate can rescue lymphoma cell killing via NKG2D; iii) this is due to inhibition of transforming growth factor-β and increase in interleukin-15 production by mesenchymal stromal cells; iv) aminobiphosphonate-treated mesenchymal stromal cells drive Vδ2 T lymphocyte differentiation into effector memory T cells, expressing the Thelper1 cytokines tumor necrosis factor-α and interferon-γ. In non-Hodgkin lymphoma lymph-nodes, Vδ2 T cells were mostly naive; upon co-culture with autologous ...
This is a small study of bone obtained following a hip fracture, so any results should be treated with caution: no observation can be made regarding bone healing, only regarding risk of fracture. However, this is the first study to link the microarchitecture, microcrack density, and mechanical strength of BP-treated bone from human patients. The most important finding is that, in a subgroup of patients who fractured after therapy, BP treatment was associated with a reduction in the compressive strength of bone, in comparison with both bone from untreated patients with hip fractures and bone from healthy non-fractured controls. The reduced strength was associated with increased microdamage, mirroring findings from animal studies.10,16-18 This deleterious effect of accumulated microcracks on compressive strength in the BP-treated patients was not offset by any detectable improvements in bone volume or other microarchitectural measures.. BP therapy was associated with a reduction in the ...
In a double-blind, randomized, placebo-controlled trial, 392 patients with advanced multiple myeloma were enrolled to receive pamidronate disodium or placebo in addition to their underlying antimyeloma therapy to determine the effect of pamidronate disodium on the occurrence of skeletal-related events (SREs). SREs were defined as episodes of pathologic fractures, radiation therapy to bone, surgery to bone, and spinal cord compression. Patients received either 90 mg of pamidronate disodium or placebo as a monthly 4 hour intravenous infusion for 9 months. Of the 392 patients, 377 were evaluable for efficacy (196 pamidronate disodium, 181 placebo). The proportion of patients developing any SRE was significantly smaller in the pamidronate disodium group (24% vs 41%, P,0.001), and the mean skeletal morbidity rate (#SRE/year) was significantly smaller for pamidronate disodium patients than for placebo patients (mean: 1.1 vs 2.1, P,0.02). The times to the first SRE occurrence, pathologic fracture, and ...
We found that first-time users of bisphosphonates are at an increased risk of scleritis and uveitis. The sensitivity analysis did not change the results for scleritis.. In light of the reported cases of inflammatory ocular adverse events with the use of oral bisphosphonates, these conditions may be more under-reported than other adverse events that are associated with the chronic use of these drugs, mainly atypical fracture1 and cancer.3 Only one epidemiologic study has examined the risk of scleritis and uveitis with the use of oral bisphosphonates.10 French and Margo10 examined the risk of uveitis and scleritis among a cohort of US veterans with a one-year follow-up period. The relative risk of scleritis and uveitis was reported to be 1.23 among bisphosphonate users but this was not statistically significant. Despite including 35 252 users of bisphosphonates, their study was limited by the small number of events, with only nine cases of uveitis and scleritis reported among first-time ...
European Multidisciplinary Conference in Thoracic Oncology news. A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, Italian researchers have found.. Dr Michela Quirino and colleagues from the Catholic University of the Sacred Heart in Rome have reported important new evidence that zoledronic acid may be able to prevent lung cancer metastases from recruiting the new blood vessels they need to survive. This process of recruiting new blood vessels is called angiogenesis.. Our investigation represents the first clear clinical evidence of the anti-angiogenic effect of zoledronic acid in patients with metastatic lung cancer, Dr Quirino said. It also represents the first biological basis in lung cancer for the clinical investigation of zoledronic acid not only for metastatic lung cancer, but also in early disease.. Dr Quirino presented findings from a ...
Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain. - Mechanism of Action & Protocol.
The treatment of choice for Pagets is potent bisphosphonates- the same class of drugs used to slow or stop bone loss in people with osteoporosis. Because not everyone with Pagets needs to be treated, doctors typically recommend bisphosphonates for people who are at risk for complications.. Bisphosphonates are usually given for a limited time, and require regular follow-up with ALP blood tests-typically every three to six months-to see if treatment is working. People whose ALP levels drop to normal are said to be in remission, and may be able to stop therapy.. While taking a bisphosphonate, it is important to consume sufficient-but not excessive-calcium and vitamin D every day, preferably through diet.. Several bisphosphonates are approved for Pagets disease. The Endocrine Society recommends a single 5 mg intravenous dose of zoledronate (Reclast), because it is well tolerated and can put people into long-term remission. People rarely need a second dose within five years.. Oral bisphosphonates ...
METHODS: Patients referred to our regional multidisciplinary pain management center who fulfilled the International Association for the Study of Pain criteria for CRPS Type I were enrolled in the study over a 2-year period. Patients were administered, intravenously, either pamidronate, 60 mg as a single dose, or normal saline. Patients pain scores, global assessment of disease severity scores, and functional assessment (SF-36) scores were documented at baseline and at 1 and 3 months.. RESULTS: Twenty-seven patients (18 female, 9 male; average age 45 years) were recruited, of whom 14 received pamidronate and 13 received placebo. Overall improvements in pain score, patients global assessment of disease severity score, and physical function (SF-36) score were noted in the pamidronate group at 3 months, and improvements in role physical (SF-36) score were noted at 1 and 3 months. There was variability in pamidronate response among individuals.. CONCLUSIONS: Pamidronate may be a useful treatment ...
β-thalassemia major (TM) is often accompanied by osteopenia or osteoporosis.1,2 Bisphosphonates have been used in the management of TM-induced bone loss.3-7 We report here the results of the long-term follow-up of our TM patients with osteoporosis who participated in a randomized, placebo-controlled trial with zoledronic acid (ZOL), the results of which at 12 months had been previously reported.5 According to that study, 66 patients with TM-induced osteoporosis (21M/45F; median age 35.5 years) were studied. Patients were blindly randomized to receive 4 mg ZOL, iv, in 15 min. infusion, every six months (group A, n=23) or every three months (group B, n=21), or to receive placebo every three months (group C, n=22), for a period of one year.. Patients of groups A and B then discontinued ZOL treatment, while patients of group C were given 4 mg ZOL, every three months, for 12 months, and subsequently stopped ZOL therapy.5 Informed consent was obtained from all patients prior to inclusion in the ...
In this report, we describe 6 children with osteogenesis imperfecta with unusual stress femoral fractures. All children were on long-term cyclic pamidronate treatment. All fractures occurred without trauma or with minimal trauma and were located in the subtrochanteric or the diaphyseal regions of the femur over preexisting intramedullary rods. These fractures have very similar features to the reported minimal trauma atypical femoral fractures in adults on long-term bisphosphonate treatment. These fractures raise concerns about the role of prolonged remodeling suppression and microdamage accumulation and the risk of increased bone fragility ...
In 2009, the global Osteoporosis drug market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa; Novartis) accounted largest share in class, respectively, and showed an average sales growth rate of about of 20% in the past 2 years. Amgens Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as second-line therapy, mostly in patients who are intolerant to Bisphosphonate. In addition to the treatment of Osteoporosis, there is substantial potential for Denosumab for treating bone loss in patients with cancer. Denosumab market is expected to reach USD 3.8 billion in 2015. Our research indicates that the ...
The clinical data upon which the NDA filing is based are from two identical pivotal studies comparing Zometa to Aredia, pamidronate disodium for injection, another Novartis agent, that at present is used in the treatment of TIH. In these studies, the combined results have showed that statistically a significant higher percentage of patients responded to Zometa 4 mg (88.4 percent) versus Aredia (70 percent), in reducing serum calcium levels to the normal range. In addition, Zometa was infused over 5 minutes, compared to Aredia, which requires approximately two or more hours of infusion.. Novartis has submitted an abstract of the clinical trial data for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, which will take place in May from 20 to 23, 2000, in New Orleans. The development of Zometa is the most recent example of Novartis long-standing commitment to the oncology community, according to David Epstein, the Chief Operating Officer at Novartis Pharmaceuticals ...
By Ingmar Ipach, Torsten Kluba & 3 more. Osteogenesis imperfecta (OI) is characterized by different signs including increased bone fragility, short stature, blue sclera, abnormal tooth growth and often secondary immobility. No curative...
Demega Formulations and Exports is a famous Exporter & Supplier of Zometa Medicine in Nagpur, Supplier of Zometa Medicine in Maharashtra, Wholesale Zometa Medicine Supplier Nagpur, Zometa Medicine Export & Supply Company in India.
Since 2011, denosumab (Dmab) subcutaneous (SC) injection is available as a superior treatment option in patients with bone metastases from solid tumours, compared with zoledronic acid (Zol) administered as an intravenous (IV) infusion. Although Zol was the mainstay treatment for skeletal-related events prevention, Dmab provides an alternative formulation to IV infusions. This Time and Motion study was conducted in Italy to estimate time endpoints associated with Dmab SC and Zol IV use ...
Forty-eight children received 158 infusions using one of the three regimens. Twenty-nine complications occurred in 24 children. A significant difference in the complication rate was present among the three regimens (P = 0.005). Nineteen children had minor complications, mainly febrile reaction or asymptomatic hypocalcaemia. Four major complications consisting of one seizure, one respiratory distress and two hypocalcaemic tetany were encountered, all with regimen B. Intraoperative complication faced was loss of position due to splintering of the cortex while rush rodding. This was seen in 20% of the long bone segments operated in those who received pamidronate as compared to 4.4% of the segments which were operated prior to the initiation of pamidronate therapy; the odds of splintering were 5.4 times higher for those patients who were bone segment rodded after pamidronate therapy ...
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject-specific sections.
Farnesyl pyrophosphate synthase (FPPS) may be the main molecular focus on of nitrogen-containing bisphosphonates (N-BPs), used clinically seeing that bone tissue resorption inhibitors. RIS using the phenyl band of Tyr204 demonstrated needed for the maintenance of the isomerized enzyme-inhibitor complicated. Research with conformationally limited analogues of RIS reaffirmed the need for Thr201 in the forming of hydrogen bonds with N-BPs. To conclude we have discovered new top features of FPPS inhibition by N-BPs and uncovered unknown roles from the energetic site residues in catalysis and substrate binding. FPPS computations from the stabilization aftereffect of Thr201 in the carbocation types (1.5?Kcal/mol) suggest a far more substantial role from the Thr201 residue in catalysis compared to the a single reported right here [35]. Compensation with the various other energetic site residues forecasted to stabilize the carbocation intermediate, such as for example Gln240 as well as the carbonyl of ...
BACKGROUND: Erosive degenerative disc disease, also known as Modic type 1 changes, is usually characterized by low back pain with an inflammatory pain pattern, as seen in spondyloarthropathies. Intravenous pamidronate has proven to be effective in patients with ankylosing spondylitis who are refractory to nonsteroidal antiinflammatory drugs, and in painful bone diseases in general, such as Pagets disease, fibrous dysplasia or vertebral fractures. We therefore hypothesize that pamidronate would be effective in treating low back pain associated with Modic type 1 changes. METHODS/DESIGN: This study, called PEPTIDE (short for the French title Etude Prospective sur lEfficacité et la tolérance du PamidronaTe dans les dIscopathies Degeneratives Erosives), will be a double-blind, randomized, placebo-controlled, parallel group, phase two clinical trial. A total of 48 patients will be recruited. These patients will be randomly assigned to one of the two groups, with 24 patients in each group: one group will
An NCI Cancer Currents blog post on a clinical trial showing that less frequent zoledronic acid treatment is effective in patients with cancer-related bone metastases.
Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit pe
The nitrogen-containing bisphosphonates (N-BPs), 4-amino-1-hydroxy-1,1-butylidenebisphosphonic acid, or Alendronate, (ALN) and 6-amino-1-hydroxy-1,1-hexylidenebisphosphonic acid, or Neridronate (NED), were studied with metal ions Mg(II), Ca(II), Cd(II) and Pb(II) at ionic strength 0.15 M at 25 oC in NaCl. The complexes of ALN and NED with Mg(II) and Ca(II) were studied by glass electrode potentiometry (GEP), and with Cd(II) and Pb(II) by sampled direct current polarography (DCP) and normal pulse polarography (NPP) at fixed total ligand to total metal concentration ratios and varied pH values. Virtual potential was used in the modelling of the metal ligand-system derived from DCP and NPP. Protonation constants and complex formation constants for ligands ALN and NED with metal ions are reported. The structures of metal-complexes proposed were compared to the reported crystal structures of the metal-complexes of the ligands ALN and NED. The linear free energy relationships (LFER) that include ...
In prostate cancer patients receiving a gonadotropin-releasing hormone agonist, a single treatment with the bisphosphonate zoledronic acid (Zometa) significantly increases bone mineral density, according to researchers at Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston.
Daiichi Sankyo Receives Approval 25 mar 2013, in Japan for Manufacture and Marketing of PRALIA ® for the osteoporosis treatment PRALIA ®subcutaneous injection 60mg syringe (INN: Denosumab; genetic recombination) for the treatment of osteoporosis. Denosumab[1] is a fully human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, multiple myeloma, and…
Bisphosphonates are synthetic analogs of pyrophosphates and they are used in the treatment of; hypercalcemia due to malignancies, multiple myeloma, bone metastases and osteoporosis. The use of these medications can minimize the risk of complications due to skeletal anomalies and they are helpful for the pain relief but they can also cause some side effects such as osteonecrosis of the jaws. In this case report, we are discussing the diagnosis and treatment approach for the oral bisphosphonate-induced osteonecrosis of the her left mandibula jaw following the tooth extraction in a 60 years old female patient, together with current literature review ...
Fracture risk thresholds may be different outside the United States.. Although a number of agents are available, the use of osteoporosis pharmacotherapy is also declining. Using commercial dispensing data, the use of oral bisphosphonates, the most commonly prescribed anti-osteoporosis pharmacotherapy, decreased by more than 50% from a peak of 31 million prescriptions dispensed in 2007 to only 14.7 million in 2012.4 Although less drastic, the sales of parenteral bisphosphonates for osteoporosis have also declined by 22% since its peak of 561,600 units in 2010 to 436,900 in 2012.4 It is speculated that declining treatment rates may be associated with a decrease in osteoporosis screening, lower physician initiation of therapy, and/or patient- or provider-initiated drug holidays, which are becoming more common because of perceived safety concerns of long-term bisphosphonate use.. The declining use of pharmacotherapy is also prevalent among those newly diagnosed with osteoporosis. In a recent study ...
Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use. This article will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development.
TY - JOUR. T1 - Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukemia and its association with mineral homeostasis and duration of inpatient stay. AU - Elmantaser, M.E.. AU - Young, David. PY - 2011/9/28. Y1 - 2011/9/28. N2 - Reduced activity, older age, and abnormal bone mineral status are considered as important determinants of poor bone health in children with acute lymphoblastic leukemia (ALL). The independent contribution of these factors toward skeletal morbidity (SM) requires further investigation. The aim of this study was to investigate the influence of activity, age, and mineral status over the first 12 months of chemotherapy on subsequent SM. The medical records of 56 children presenting with ALL between 2003 and 2007 and treated on UKALL2003 were reviewed for the number of inpatient days over the first 12 months of chemotherapy as a surrogate marker of inactivity and lack of well-being. Data for serum Ca, albumin, Mg, and Pho were also collected over ...
DENVER -- Biochemical markers of bone turnover showed significantly faster responses on initiation of once-yearly zoledronic acid (Reclast) infusion than with weekly oral alendronate (Fosamax).
Todays Daily Dose brings you news about Amgens multiple myeloma trial results with XGEVA; Mercks findings from Cohort 1 of phase 2 registrational trial of KEYTRUDA in gastric cancer patients; Prima BioMeds phase II results of IMP321 in breast cancer; TG Therapeutics phase III study results of TG-1101 in patients with previously treated high risk Chronic Lymphocytic Leukemia and NewLinks disappointment in phase II trial of Indoximod in breast cancer.. Read on…. Amgen (AMGN) on Sunday announced that its drug XGEVA has proven to be non-inferior to Zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma in a phase III trial. XGEVA-treated patients also had a significantly lower rate of renal adverse events compared to Zometa in the study.. Amgens XGEVA is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors, and for the treatment of giant cell tumor of the bone. XGEVA is currently ...
Results We identified 2006 bisphosphonate initiators, who were matched to 2006 non-initiators(mean age 76, mean body mass index 27), with mean follow-up time of 3 years. The crude incidence rate of KR was 22.0 per 1000 person-years among the initiators, and 29.1 among the non-initiators. Bisphosphonate initiators had 26% lower risk of KR than non-initiators(HR 0.74, 95% CI 0.59 to 0.93); these results were similar when additionally adjusted for potential confounders in the propensity score (HR 0.76, 95% CI 0.60 to 0.95). Results of sensitivity analyses supported this protective effect. ...
When I saw Gini at the clinic in early February, things were so stable we decided I didnt need to come back for three months. Unfortunately, I didnt realize the effect some treatment changes would have on my pain in the interim. In late January, after a short chemo break, I was switched to daily Tamoxifen pills. My late January CT scan found a tumour on my right femoral neck that put me at risk of fracture and was subsequently treated with radiation. In March, I started a double-blind clinical trial where I was either continuing my bone-building Pamidronate treatment (but every four weeks instead of three) or I was getting Zometa, a similar drug. Put them all together and my pain, or rather my pains, increased. I was taking long-acting hydromorphone contin (a narcotic), Lyrica (for nerve pain) and Naprosyn (an anti-inflammatory) as well as hydromorphone (AKA Dilaudid) for breakthrough pain. I was taking enough to address the bone and nerve pain caused by my tumours and fractures, as well as ...
Dental implant treatment considerations for patients taking Bisphosphonates (both oral and intravenous) are used to manage osteoporosis and types of cancers.
Two identical multicenter, randomized, double-blind, double-dummy studies of zoledronic acid 4 mg given as a 5-minute intravenous infusion or pamidronate 90 mg given as a 2-hour intravenous infusion were conducted in 185 patients with hypercalcemia of malignancy (HCM). NOTE: Administration of zoledronic acid 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity, as measured by increases in serum creatinine, which can progress to renal failure. The incidence of renal toxicity and renal failure has been shown to be reduced when zoledronic acid 4 mg is given as a 15-minute intravenous infusion. Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [see Warnings and Precautions (5.1 and 5.2) and Dosage and Administration (2.4)]. The treatment groups in the clinical studies were generally well balanced with regards to age, sex, race, and tumor types. The mean age of the study population was 59 ...
There is no toxicokinetic data available for HEDP potassium salt, therefore all data were read-across from HEDP sodium salt. Based on the available data, no major differences appear to exist between animals and humans with regard to the absorption, distribution and elimination of phosphonic acid compounds in vivo. Uptake and elimination of potassium HEDP (CAS No 67953 -76 -8) by humans is generally consistent with that seen in animals. The toxicokinetics of the sodium and potassium salts of HEDP are not expected to be different to those of the parent acid, as the salts are well water soluble and the dissociation is mainly dependent on the ambient pH in the gastrointestinal tract. During in vivo toxicity studies the local pH and ionic conditions within the stomach, GI tract etc. dominate the speciation of the phosphonate, irrespective of the form originally dosed. At a defined pH, a salt will behave no differently to the parent acid, at identical concentration of the particular speciated form ...
Wong, K. K.; Piert, M. (12 March 2013). "Dynamic Bone Imaging with 99mTc-Labeled Diphosphonates and 18F-NaF: Mechanisms and ... Use of technetium-99m (99mTc) labelled phosphates, diphosphonates or similar agents, as in the modern technique, was first ... The most common radiopharmaceutical for bone scintigraphy is 99mTc with methylene diphosphonate (MDP). Other bone ... Chopra, A (2004). "99mTc-Methyl diphosphonate". Molecular Imaging and Contrast Agent Database. National Center for ...
They are thus also called diphosphonates (bis- or di- + phosphonate). Evidence shows that they reduce the risk of fracture in ... The non-nitrogenous bisphosphonates (diphosphonates) are metabolised in the cell to compounds that replace the terminal ...
"Bone extraction and blood clearance of diphosphonate in the dog". Am J Physiol. 232 (3): H341-7. doi:10.1152/ajpheart.1977.232. ...
... the dynamics of its subcellular localization and the cellular effects of a diphosphonate". J. Biol. Chem. 278 (2): 1075-1085. ... "Differential sensitivity of membrane-associated pyrophosphatases to diphosphonates and fluoride delineates two classes of ...
Prenatal and postnatal treatment with low-dose, cyclical bisphosphonates, also called diphosphonate, resulted in a complete ... Failure of treatment with diphosphonate". Heart. 64 (2): 156-9. doi:10.1136/hrt.64.2.156. PMC 1024357. PMID 2118367. Bellah, ...
For example, the ligand methylene-diphosphonate (MDP) can be preferentially taken up by bone. By chemically attaching ...
"Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate". Seminars in Nuclear Medicine. 31 ...
... (conjugate base, medronate), also known as methylene diphosphonate, is the smallest bisphosphonate. Its complex ...
DPD is a diphosphonate and can be used as an alternative to HDP or MDP in nuclear medicine bone scintigraphy. DPD scanning ...
... diphosphonate, entrepreneurialism, forbearance, and googley'. Because players could see the responses of their partner at the ...
... diphosphonate, vasopressin analogues. Antifungal, alkalinizing agents, quinolones, antibiotics, cholinergics, anticholinergics ...
The drug is a complex of medronic acid (MDP, methylene diphosphonate), the simplest bisphosphonate, with technetium-99m (99mTc ...
The efficacy of other treatments, such as magnesium or aluminum antacids, sodium etidronate, diphosphonates and diltiazem is ...
... also known as bipolar disorder Mesolimbic dopamine pathway of the brain Methylene diphosphonate, a pharmaceutical product used ...
Chelate MPI Indium DTPA In 111 MPI Krypton 81m Gas Generator MPI Stannous Diphosphonate MS Contin Mucinex Mucomyst Mucosil ...
... diphosphonate - dipyridamole - disease progression - disease-free survival - disease-specific survival - distal - distal ...
... diphosphonate, vasopressin analogues ...
diphosphonate synonyms, diphosphonate pronunciation, diphosphonate translation, English dictionary definition of diphosphonate ... Diphosphonate - definition of diphosphonate by The Free Dictionary https://www.thefreedictionary.com/diphosphonate ... diphosphonate. Also found in: Medical, Wikipedia. di·phos·pho·nate. (dī′fŏs′fə-nāt′). n.. Variant of bisphosphonate. ... Technetium-99m-methylene diphosphonate ([sup.99m]Tc-MDP) bone scan revealed a focus of intense tracer uptake in the proximal ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
The present invention relates to methods of use of phosphonate-phosphates and diphosphonates to modulate apolipoprotein E ... 1-diphosphonate; tetramethyl 3-(phenoxypropylidene)1,1-diphosphonate; and tetramethyl 4-(phenoxybutylidene)1,1-diphosphonate. 6 ... 1-diphosphonate; tetramethyl 3-(phenoxypropylidene)1,1-diphosphonate; and tetramethyl 4-(phenoxybutylidene)1,1-diphosphonate. ... 1. Phosphonate-Phosphate and Diphosphonate Compounds The present invention relates to phosphonate-phosphate and diphosphonate ...
... diphosphate/diphosphonate-based POMs represent a more recent area of study. However, in this short time it has emerged to ... Diphosphates and diphosphonates in polyoxometalate chemistry† Abhishek Banerjee,a Bassem S. Bassil,a Gerd-Volker Röschenthalera ... Diphosphates and diphosphonates in polyoxometalate chemistry A. Banerjee, B. S. Bassil, G. Röschenthaler and U. Kortz, Chem. ... chemistry, diphosphate/diphosphonate-based POMs represent a more recent area of study. However, in this short time it has ...
Parathyroid Hormone Effects in Rats Treated with Diphosphonate Message Subject. (Your Name) has forwarded a page to you from ... The ability of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP; 40 milligrams per kilogram of body weight per day) to reduce ...
... and two diphosphonates, disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) and disodium dichloromethylene diphosphonate... ... La liaison du pyrophosphate inorganique (PPi) et de deux diphosphonates, léthane-1-hydroxy-1,1-diphosphonate disodique (EHDP) ... 1-diphosphonate (EHDP) and disodium dichloromethylene diphosphonate (Cl2MDP). The binding is greatest for PPi, less for EHDP ... Smith, R., Russell, R. G. G., Bishop, M.: Diphosphonates and Pagets disease of bone. Lancet1971I, 945-947.Google Scholar ...
Water Oxidation by Ruthenium Complexes Incorporating Multifunctional Bipyridyl Diphosphonate Ligands Journal Article Xie, Yan ... Water Oxidation by Ruthenium Complexes Incorporating Multifunctional Bipyridyl Diphosphonate Ligands Journal Article Xie, Yan ... Here, we describe herein the synthesis and characterization of ruthenium complexes with multifunctional bipyridyl diphosphonate ... title = {Water oxidation by Ruthenium complexes incorporating multifunctional biipyridyl diphosphonate ligands},. author = {Xie ...
... diphosphonate explanation free. What is diphosphonate? Meaning of diphosphonate medical term. What does diphosphonate mean? ... Looking for online definition of diphosphonate in the Medical Dictionary? ... diphosphonate. Also found in: Dictionary, Wikipedia. diphosphonate. [di-fos´fo-nāt] any of a group of related phosphorus- ... diphosphonate. /di·phos·pho·nate/ (di-fos´fŏ-nāt) 1. a salt, ester, or anion of a dimer of phosphonic acid, structurally ...
Idiopathic infantile arterial calcification in two siblings: failure of treatment with diphosphonate. ... Idiopathic infantile arterial calcification in two siblings: failure of treatment with diphosphonate. ...
... diphosphonates with a 3D supramolecular structure, M(hedpH2)3·3NH2(CH3)2NH(CH3)3·3H2O (M = Mn (1), Co (2), Ni (3), Zn (4); ... Four new transition metal(II) diphosphonates with a 3D supramolecular structure, M(hedpH2)3·3NH2(CH3)2NH(CH3)3·3H2O (M = Mn (1 ... structures, luminescent and surface photovoltage properties of four new transition metal diphosphonates with a 3D ... structures, luminescent and surface photovoltage properties of four new transition metal diphosphonates with a 3D ...
1. The diphosphonates, disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) and disodium dichloromethylene diphosphonate (Cl2MDP ... adenosine 3′:5′-cyclic monophosphate, bone, dichloromethylene diphosphonate, diphosphonates, ethane-1-hydroxy-1, 1- ... Effect of Diphosphonates on Adenosine 3′:5′-Cyclic Monophosphate in Mouse Calvaria after Stimulation by Parathyroid Hormone in ... U. Gebauer, R. G. G. Russell, M. Touabi, H. Fleisch; Effect of Diphosphonates on Adenosine 3′:5′-Cyclic Monophosphate in Mouse ...
Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases Knut Liepe, Reiner Hliscs, ... Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases ... Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases ...
2. The effect of a diphosphonate, disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP), given in the drinking water at ... The Effects of a Diphosphonate and Dietary Calcium on the Metabolism of Vitamin D 3 (Cholecalciferol) in the Chick Clin Sci Mol ... bladder stones, disodium ethane-1-hydroxy-1,1-diphosphonate, urinary stones, calcium oxalate ... The Influence of Disodium Ethane-1-Hydroxy-1,1-Diphosphonate (Ehdp) on the Development of Experimentally Induced Urinary Stones ...
Dual-Isotope SPECT Using 99mTc-Hydroxymethylene Diphosphonate and 201Tl-Chloride to Assess Mandibular Invasion by Intraoral ... Tsuchimochi M, Katagiri M, Maeda K, Kato J. Autoradiographic evaluation of 99mTc-methylene diphosphonate accumulation in oral ... Dual-Isotope SPECT Using 99mTc-Hydroxymethylene Diphosphonate and 201Tl-Chloride to Assess Mandibular Invasion by Intraoral ... Dual-Isotope SPECT Using 99mTc-Hydroxymethylene Diphosphonate and 201Tl-Chloride to Assess Mandibular Invasion by Intraoral ...
186Re-labeled HEDP4 and 153Sm-labeled EDTMP are radioactive metal diphosphonates (6, 7, 8, 9, 10) in which bone localization is ... Imaging studies included a radionuclide bone scan performed with 99mTc-labeled methylene diphosphonate. Patients with symptoms ... A similar dissociation has been observed with low-dose corticosteroids, cold diphosphonates, and the bone resorption inhibitor ... Rhenium-186 (tin)-labeled hydroxyethylidene diphosphonate (186Re-labeled HEDP) was evaluated in 27 men with progressive ...
Objective. We introduce the use of 99mTc-hydroxymethylene diphosphonate (HDP) digital blood flow scintigraphy to diagnose ... Diagnosis of Raynauds Phenomenon by 99mTc-Hydroxymethylene Diphosphonate Digital Blood Flow Scintigraphy After One-hand ... Diagnosis of Raynauds Phenomenon by 99mTc-Hydroxymethylene Diphosphonate Digital Blood Flow Scintigraphy After One-hand ... Diagnosis of Raynauds Phenomenon by 99mTc-Hydroxymethylene Diphosphonate Digital Blood Flow Scintigraphy After One-hand ...
We have observed focal skeletal muscle uptake of 99mTechnetium-hydroxymethylene diphosphonate (Tc-HDP), which could mimic a ... Focal skeletal muscle uptake of 99mTechnetium-hydroxymethylene diphosphonate following peroneal nerve blocks in horses. ...
... diphosphonate/ACM94201997 can be provided in Alfa Chemistry. We are dedicated to provide our customers the best products and ... Home > Product > Heterocyclic Organic Compound > Trisodium hydrogen[[(3,5,5-trimethylhexyl)imino]bis(methylene)]diphosphonate ... Trisodium hydrogen[[(3,5,5-trimethylhexyl)imino]bis(methylene)]diphosphonate , CAS Number: 94201-99-7. ...
Fingerprint Dive into the research topics of Treatment of osteoporosis with diphosphonates.. Together they form a unique ...
Diphosphonates. A very important new drug type used to prevent or treat high calcium levels in cancer. It is very useful in ... It is now commonly controlled by tablets or infusion of bonefos or aredia (diphosphonates) ...
Tc-99m-diphosphonate abdominal imaging in necrotizing enterocolitis: A prospective study. G. N. Sfakianakis, V. N. Ortiz, G. M ... Tc-99m-diphosphonate abdominal imaging in necrotizing enterocolitis: A prospective study. Journal of Nuclear Medicine. 1978;19( ... Tc-99m-diphosphonate abdominal imaging in necrotizing enterocolitis : A prospective study. / Sfakianakis, G. N.; Ortiz, V. N.; ... Sfakianakis, G. N., Ortiz, V. N., Haase, G. M., & Boles, E. T. (1978). Tc-99m-diphosphonate abdominal imaging in necrotizing ...
diphosphonate * 1-(4-Pyridinyl)-2-Propanone [6304-16-1] * N-Hydroxy-5-norbornene-2,3-dicarboxylic acid imide(HONB) [21715-90-2 ... Xylylenediphosphonate 4546-04-7 , Tetraethyl P-Xylylenediphosphonate , Xylylenediphosphonate diphosphonate Phosphonic acid, P,P ...
Diphosphonates.. Gallez B, Osinski P, Adline J, Dumont P.. Int J Rad Appl Instrum A. 1988;39(9):1011-4. ...
LIPOSOME ENCAPSULATED DICHLOROMETHYLENE DIPHOSPHONATE. Multilamellar liposomes encapsulating the drug clodronate: ... dichloromethylene diphosphonate (CL2MDP) were prepared as described earlier.17 Clodronate was kindly provided by Boehringer ... depletion of synovial lining cells after intraarticular treatment with liposome encapsulated dichloromethylene diphosphonate. ...
A simple method for estimating the skeletal uptake of diphosphonates. GALLI, G.; BAGNATO, A.; GALLI, M. ...
Atypical Femur Fractures Associated With Diphosphonate Use. Balach, Tessa; Baldwin, Paul C.; Intravia, Jessica ...
This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I).. The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and an extended follow-up period with visits at Month 6, Month 9, and Month 12. The extended follow-up period will be terminated for all participants after the last participant enrolled completes their Month 6 visit (Visit 9). The double-blind will be maintained throughout the 12-week trial period and extended follow-up period. ...
The purpose of this research study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases. The blood test will look for a protein, called TRAP, which is released into the blood stream by the breakdown of bone. This study will compare the TRAP blood test with other blood tests for bone destruction ...
  • Bone scintigraphy with [.sup.99m]Tc-methylene diphosphonate revealed increased osteoblastic activity in the manubriosternal, bilateral sternocostoclavicular, and lower cervical vertebral regions (Figure 1a). (thefreedictionary.com)
  • Calcification in these tumours leads to Technetium labeled Methylene Diphosphonate (Tc99m-MDP) uptake on skeletal scintigraphy. (thefreedictionary.com)
  • Radionuclide diagnosis of vertebral osteomyelitis: indium-111-leukocyte and technetium-99m-methylene diphosphonate bone scintigraphy. (thefreedictionary.com)
  • 99m technetium methylene diphosphonate bone scintigraphy did not reveal any sacroiliac joint involvement. (thefreedictionary.com)
  • Technetium-99m-methylene diphosphonate ([sup.99m]Tc-MDP) bone scan revealed a focus of intense tracer uptake in the proximal ulna [Figure 3b]. (thefreedictionary.com)
  • sup.99m]Tc-methylene diphosphonate (MDP) planar bone scan or single-photon emission computed tomography (SPECT) is widely used as noninvasive methods for detecting osseous metastases. (thefreedictionary.com)
  • 99m]Tc methylene diphosphonate is exquisitely sensitive because the radiotracer accumulates at sites of osteoblastic activity. (thefreedictionary.com)
  • 16) Several studies have reported improved detection of both benign and malignant bone lesions with NaF PET compared to technetium methylene diphosphonate (TcMDP), although most of these were performed on adults. (thefreedictionary.com)
  • Technetium-99m methylene diphosphonate (Tc-99m MDP) three-phase bone scintigraphy (TPBS) confirmed the clinical diagnosis of bilateral CRPS by detecting the mild or intense increased activity uptake in a dynamic, early blood pool, especially in delayed static images (Figure 3). (thefreedictionary.com)
  • Tenebaum F, Schlumberga M, Bonnin F, et al: Usefulness of technetium-99m hydroxy methylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma. (thefreedictionary.com)
  • SPECT-CT for characterization of extraosseous uptake of 99mTc-methylene diphosphonate on bone scintigraphy. (thefreedictionary.com)
  • b) Technetium 99m-methylene diphosphonate bone scan showed a focus of intense tracer uptake in the proximal ulna. (thefreedictionary.com)
  • Hasbak, "Chronic recurrent multifocal osteomyelitis demonstrated by Tc-99m methylene diphosphonate bone scan," Clinical Nuclear Medicine, vol. (thefreedictionary.com)
  • Plain x-rays of the femora were normal, whereas the initial Tc-99m methylene diphosphonate (MDP) bone scan showed several foci with increased activity in both femurs. (qxmd.com)
  • Comparison of Tc-99m methylene diphosphonate, Tc-99m human immune globulin, and Tc-99m-labeled white blood cell scintigraphy in the diabetic foot. (qxmd.com)
  • Comparison of magnetic resonance imaging and 99mTechnetium-labelled methylene diphosphonate bone scintigraphy in the initial assessment of chronic non-bacterial osteomyelitis of childhood and adolescents. (qxmd.com)
  • Animal studies show that Tc-99m HMDP has a higher uptake on bone and a more rapid clearance from the blood than any of the three technetium-labeled bone imaging agents in current use: Tc-99m methylene diphosphonate (MDP), Tc-99m (1-hydroxyethylidene) diphosphonate (HEDP), and Tc-99m pyrophosphate (PPi). (osti.gov)
  • Despite the high sensitivity , Tc-99m methylene diphosphonate (MDP) is not a specific tracer and its increased uptake may also be seen in extra-osseous areas. (bvsalud.org)
  • To analyze the effects of technetium99 conjugated with methylene diphosphonate(99Tc-MDP) on adjuvant arthritis in rats . (bvsalud.org)
  • The most common radiopharmaceutical for bone scintigraphy is 99mTc with methylene diphosphonate (MDP). (wikipedia.org)
  • For example, the ligand methylene-diphosphonate (MDP) can be preferentially taken up by bone. (wikipedia.org)
  • To investigate the presence of other osteoarticular involvement, technetium-99m hydroxymethylene diphosphonate ([sup.99m]Tc-HMDP) scintigraphy was performed, which demonstrated diffuse increased uptake at the right mandible, as well as in the sternum and the sternocostoclavicular joints (Figure 4). (thefreedictionary.com)
  • We introduce the use of 99m Tc-hydroxymethylene diphosphonate (HDP) digital blood flow scintigraphy to diagnose Raynaud's phenomenon (RP). (jrheum.org)
  • A 30-year-old guy underwent Tc-99m dicarboxypropane diphosphonate bone tissue scintigraphy to judge the reason for upper body and back again wall structure discomfort. (bx-795.com)
  • Skeletal scintigraphy with technetium-99m diphosphonates has high sensitivity but low specificity. (medscape.com)
  • We have observed focal skeletal muscle uptake of 99mTechnetium-hydroxymethylene diphosphonate (Tc-HDP), which could mimic a tibial lesion, in horses following peroneal nerve blocks. (avmi.net)
  • The binding on hydroxyapatite has been studied of inorganic pyrophosphate (PP j ) and two diphosphonates, disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) and disodium dichloromethylene diphosphonate (Cl 2 MDP). (springer.com)
  • 1. The diphosphonates, disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) and disodium dichloromethylene diphosphonate (Cl 2 MDP), inhibit bone resorption in animals and in explanted bone in tissue culture. (portlandpress.com)
  • 2. The effect of a diphosphonate, disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP), given in the drinking water at concentrations of 0·0025, 0·05 and 0·5% (w/v), on the size and composition of these stones was examined. (portlandpress.com)
  • Eight patients with absorptive hypercalciuria and renal stones received disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP) orally at dosages ranging from 5 to 20 mg/kg/day. (elsevier.com)
  • The drugs Pamidronate and Diphosphonates have been mentioned in the context of this disorder. (malacards.org)
  • La liaison du pyrophosphate inorganique (PP i ) et de deux diphosphonates, l'éthane-1-hydroxy-1,1-diphosphonate disodique (EHDP) et le dichlorométhylène diphosphonate disodique (Cl 2 MDP), sur l'hydroxyapatite a été étudiée. (springer.com)
  • Pyrophosphate and diphosphonates in calcium metabolism and their possible role in renal failure. (ox.ac.uk)
  • We examined mandibular invasion of intraoral squamous cell carcinoma by simultaneous bone and tumor dual-isotope SPECT using 99m Tc-hydroxymethylene diphosphonate ( 99m Tc-HMDP) and 201 Tl-chloride ( 201 Tl) and by CT. (snmjournals.org)
  • The purpose of this study was to use simultaneous bone and tumor dual-isotope SPECT for colocalization of bone- and tumor-specific radiopharmaceuticals-namely, 99m Tc-hydroxymethylene diphosphonate ( 99m Tc-HMDP) and 201 Tl-in patients with suspected mandibular invasion by intraoral squamous cell carcinoma. (snmjournals.org)
  • Tc-99m HMDP (Hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. (osti.gov)
  • Technetium-99m hydroxymethylene diphosphonate (Tc-99m HMDP) is a new diphosphonate skeletal imaging agent. (osti.gov)
  • Dijkstra, "Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate ," Cell and Tissue Research, vol. (thefreedictionary.com)
  • Use of technetium-99m (99mTc) labelled phosphates, diphosphonates or similar agents, as in the modern technique, was first proposed in 1971. (wikipedia.org)
  • The bisphosphonates (at that time called diphosphonates), characterized by P-C-P motifs, were among these classes. (aappublications.org)
  • Rhenium-186 (tin)-labeled hydroxyethylidene diphosphonate ( 186 Re-labeled HEDP) was evaluated in 27 men with progressive androgen-independent prostate cancer and bone metastases. (aacrjournals.org)
  • Ohata, M & Pak, CYC 1974, ' Preliminary study of the treatment of nephrolithiasis (calcium stones) with diphosphonate ', Metabolism , vol. 23, no. 12, pp. 1167-1173. (elsevier.com)
  • 186 Re-labeled HEDP 4 and 153 Sm-labeled EDTMP are radioactive metal diphosphonates (6 , 7 , 8 , 9 , 10) in which bone localization is provided by the diphosphonate moiety, whereas the radioactive label simultaneously emits gamma energies for imaging and β energies for therapy. (aacrjournals.org)
  • Intravia, "Atypical femur fractures associated with diphosphonate use," Journal of the American Academy of Orthopaedic Surgeons, vol. (thefreedictionary.com)
  • Effect of diphosphonate binding to collagen upon inhibition of calcification and promotion of spontaneous endothelial cell coverage on tissue valve prostheses," ASAIO transactions/American Society for Artificial Internal Organs, vol. (thefreedictionary.com)
  • Idiopathic infantile arterial calcification in two siblings: failure of treatment with diphosphonate. (bmj.com)
  • In the wide area of polyoxometalate ( POM ) chemistry, diphosphate/diphosphonate-based POMs represent a more recent area of study. (rsc.org)
  • The diagnostic value of Tc-99m diphosphonate bone imaging in transient osteoporosis of the hip. (thefreedictionary.com)
  • Treatment of osteoporosis with diphosphonates. (elsevier.com)
  • Fingerprint Dive into the research topics of 'Treatment of osteoporosis with diphosphonates. (elsevier.com)
  • Here, we describe herein the synthesis and characterization of ruthenium complexes with multifunctional bipyridyl diphosphonate ligands as well as initial water oxidation studies. (osti.gov)
  • article{osti_1333198, title = {Water oxidation by Ruthenium complexes incorporating multifunctional biipyridyl diphosphonate ligands}, author = {Xie, Yan and Shaffer, David W. and Lewandowska-Andralojc, Anna and Szalda, David J. and Concepcion, Javier J.}, abstractNote = {Here, we describe herein the synthesis and characterization of ruthenium complexes with multifunctional bipyridyl diphosphonate ligands as well as initial water oxidation studies. (osti.gov)
  • Conversely, OTM decreased with an increase in bone minerals after diphosphonate treatment [14-16]. (thefreedictionary.com)
  • 4. It is suggested that the inhibition of adenylate cyclase is not an essential feature of the reduction of bone resorption by diphosphonates, which may act by direct inhibitory effects on the dissolution of hydroxyapatite and perhaps by other unidentified effects on bone cells. (portlandpress.com)
  • The main focus of such a study is based on factors such as the oxidation state of the metal, the effect of pH and temperature during synthesis, and the presence of different functional groups on the diphosphonate. (rsc.org)
  • The present invention relates to methods of use of phosphonate-phosphates and diphosphonates to modulate apolipoprotein E levels and the use of such compounds in therapy, including cardiovascular and neurological disease states. (freepatentsonline.com)
  • Myositis ossificans progressiva, a case report and clinical observation of diphosphonate therapy. (nii.ac.jp)
  • A new molybdenum diphosphonate network structure has been prepared and structurally characterised. (bath.ac.uk)
  • Le texte complet de cet article est disponible en PDF. (urofrance.org)